Technology | December 11, 2013

C4 Imaging Announces FDA 510(k) Clearance of Sirius Positive-Signal MRI Marker

Mri systems brachytherapy prostate technology c4 imaging sirius mri marker
December 11, 2013 — C4 Imaging LLC announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its first product, the Sirius MRI Marker. The positive-signal magnetic resonance imaging (MRI) marker will be used following treatment of prostate cancer with brachytherapy to facilitate seed localization within the prostate, utilizing a single post-implant MRI procedure.
 
Brachytherapy, or radioactive seed implantation, is a standard option for the curative treatment of prostate cancer. Brachytherapy involves implanting around 100 radioactive seeds into the prostate. Its popularity has increased due to its effectiveness, convenience, relatively low incidence of erectile dysfunction and minimal invasiveness [1]. Radiation released from the seeds penetrates the surrounding prostate tissue at a limited distance, with most of the radiation concentrated within the prostate. Outcomes after brachytherapy depend greatly on the quality of the implant: eight-year prostate-specific antigen (PSA) relapse-free survival rates of 93 percent for high-quality implants versus 76 percent for low-quality implants have been reported [2].
 
"A Positive-Signal MRI marker can enhance seed detection. This represents a significant advancement for prostate brachytherapy," said Steven Frank M.D., founder and chairman, C4 Imaging. "If seeds can be readily localized with MRI, it would lead to more effective treatment and better patient outcomes."
 
"The encapsulation of a contrast agent within a permanently implantable device allows positive MRI seed localization after brachytherapy to be offered to more than 200,000 men diagnosed with prostate cancer in the U.S. each year [3]," said Andrew Bright, president and CEO, C4 Imaging.
 
"With our 510(k) now cleared, we're actively pursuing options for supplying Sirius to physicians treating prostate cancer in the U.S., as well as seeking regulatory clearance in Canada and Europe,” Bright added.
 
For more information: www.c4imaging.com
 
References
[1] Frank SJ, et al. American College of Radiology Appropriateness Criteria Permanent Source Brachytherapy for Prostate Cancer. Brachytherapy. 2011; 10(5): 357-362.
[2] Zelefsky MJ, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int. J.   Radiat. Oncol. Biol. Phys. 2007; 67(2): 327-333.
[3] American Cancer Society. Cancer Facts & Figures 2013. Atlanta: American Cancer Society; 2013.

Related Content

Technology | Focused Ultrasound Therapy | June 19, 2018
EDAP TMS SA has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Focal One device for...
New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Florida Hospital First in State to Adopt NeuroLogica's BodyTom Elite CT
News | Computed Tomography (CT) | June 14, 2018
June 14, 2018 — NeuroLogica, a subsidiary of Samsung Electronics Co.
Hitachi Medical Systems Europe Named Imaging Supplier for London Prostate Cancer Program
News | Prostate Cancer | June 14, 2018
Hitachi Medical Systems Europe has been awarded the contract to supply six ultrasound systems as part of the RAPID...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Reduced hippocampal volume on MRI

This figure shows reduced hippocampal volume over the course of 6 years as seen on progressive volumetric analysis and also coronal MRI evaluations (arrows).Progressive volume loss in the mesial temporal lobe on MRI is a characteristic imaging feature of AD. This patient was a case of Alzheimer’s Dementia.

 

News | Neuro Imaging | June 12, 2018
According to a UCLA Medical Center study, a new technology shows the potential to help doctors better determine when...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
High Prevalence of Atherosclerosis Found in Lower Risk Patients
News | Magnetic Resonance Imaging (MRI) | June 08, 2018
Whole-body magnetic resonance angiography (MRA) found a surprisingly high prevalence of atherosclerosis in people...
Overlay Init